AHRQ's Tech-Assessment Program Seeks Comments for CYP2D6, KRAS, BCR-ABL1 Dxs

By Kirell Lakhman

AHRQ's Technology Assessment Program yesterday issued a call for public comment on certain pharmacogenomic lab tests: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia.

The comment period runs through Feb. 12.

The Call for Public Review document can be found here.